Using Synthesis And Route Design Technology To Approach API Complexity

By Dr. Ryan Littich, Head of Advanced Chemistry Technologies, Global R&D, Lonza, and Dr. Juergen Swienty-Busch, Director of Product Management for Chemistry, Elsevier Information Systems

Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. As a result, API syntheses are growing longer and, at times, undermining drug sponsors’ speed-to-clinic. These longer synthetic pathways present challenges for process chemists hoping to achieve an efficient API manufacturing process, due to factors such as elaborate raw material needs and supply chain obstacles. These compounding layers can delay start times and extend preclinical development.

To help mitigate these issues for sponsors, Lonza Small Molecules has partnered with Elsevier Information Systems to leverage a synthesis planning and route scouting solution that combines Lonza’s intellectual property (IP) with Elsevier’s AI-enabled route design technology – Reaxys predictive retrosynthesis. The Reaxys predictive retrosynthesis model leverages AI and machine learning technologies to extract and prioritize transformation rules automatically to generate robust predicted routes within minutes. Download the full article to explore how using these tools in concert can lead drug developers to save time and money on their route to the clinic.